10-Q: CNBX Pharmaceuticals Q3 2026 Financial Update

CNBX Pharmaceuticals reports a net loss of $154,165 for the third quarter of 2026 as it continues to develop its oncology drug candidate, RCC-33.

Summary

• Net loss for the three months ended May 31, 2026, was $154,165, compared to $59,727 in the same period last year.
• Operating expenses increased to $162,763 for the quarter, up from $40,380 in the prior year period.
• Cash and cash equivalents stood at $9,487 as of May 31, 2026, down from $15,111 at August 31, 2025.
• The company issued 921,805,889 shares during the period due to the conversion of loans and interest totaling $148,561.
• Total current liabilities reached $2,672,509, including $1,460,077 due to related parties.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the severe liquidity constraints, recurring losses, and the necessity for further dilutive financing to maintain operations.

Positives

• The company continues to advance its lead drug candidate, RCC-33, for colorectal cancer.
• Management successfully negotiated forbearance agreements with institutional investors, extending relief until September 30, 2026.

Negatives

• The company reported a net loss of $311,982 for the nine months ended May 31, 2026.
• Cash reserves are critically low at $9,487, raising significant concerns regarding liquidity.
• Substantial dilution occurred during the period, with common shares outstanding increasing significantly due to debt conversions.
• Accumulated deficit has grown to $25,580,358.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern due to recurring losses and limited cash.
• The company requires additional capital to fund operations and clinical development, with no current arrangements in place.
• Heavy reliance on debt financing and potential for further equity dilution.
• The business is in a pre-clinical stage with no revenue-generating products.

Future Outlook

The company expects to incur at least $1,000,000 in expenses over the next twelve months for operations, overhead, and clinical development. It aims to initiate Phase I/II clinical trials for RCC-33 in 2027, contingent upon securing necessary funding.

Management Comments

• Management acknowledges that the company's ability to continue as a going concern is dependent on generating revenue or raising additional capital.
• The company plans to advance its programs through clinical studies and potentially seek partnerships or acquisitions.

Industry Context

StockSavvy.ai notes that CNBX operates in the high-risk, capital-intensive pre-clinical biopharmaceutical sector, where companies frequently face liquidity challenges and rely on dilutive financing to sustain research and development efforts.

Comparison to Industry Standards

• The company's reliance on convertible debt and subsequent equity dilution is common among micro-cap biotech firms.
• The lack of revenue is typical for a pre-clinical stage company, though the cash-to-burn ratio is significantly tighter than industry peers.

Corporate Governance

Legal Proceedings

• None.

Related Party Transactions

• Accrued $189,286 in salaries to the CEO and Chairman during the nine months ended May 31, 2026.
• Outstanding payable of $1,213,166 to directors Gabriel Yariv and Eyal Barad.
• Outstanding payable of $223,645 to Cannabics, Inc.

Stakeholder Impact

• Shareholders face significant dilution risk due to ongoing debt-to-equity conversions.
• Creditors are subject to forbearance agreements regarding repayment terms.

Next Steps

• Initiate Phase I/II clinical trials for RCC-33 in 2027.
• Seek additional capital to fund operations for the next twelve months.
• Manage debt obligations under existing forbearance agreements.

Key Dates

Recommendation

The company's precarious financial position, characterized by minimal cash reserves, high debt, and the need for significant future capital raises, presents an extremely high risk for investors.

Keywords

CNBX, biopharmaceutical, oncology, colorectal cancer, RCC-33, clinical trials, going concern